Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05917015
Other study ID # 202206CT
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 6, 2023
Est. completion date December 31, 2023

Study information

Verified date June 2023
Source USANA Health Sciences
Contact Mark Levy
Phone 801 954 7783
Email mark.levy@usanainc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to determine if a dieatary supplement containing beta-glucan can reduce the incidence, severity and duration of upper respiratory tract infections among a group of highly trained athletes


Description:

In this study, we hypothesize that consumption of 200 mg beta-glucan per day will lessen the frequency, duration and severity of URTI symptoms in a population of elite, internationally competitive skiers over a 45-day period. In order to complete this objective, we will utilize the Wisconsin Upper Respiratory Symptom Survey-24 (WURSS-24) to monitor and quantify the incidence, duration and severity of URTI symptoms. A secondary objective is to determine if beta-glucan supplementation reduces or mitigates early indictors of athlete-specific stress. This objective will be assessed using the Athlete Psychological Strain Questionnaire (APSQ), a 10-question patient-reported outcome tool used to evaluate athlete-specific psychological stress. This will be a randomized, double blind, placebo controlled, parallel arm design conducted over a 6-week period. 50-60 healthy subjects will be recruited and randomized in a 1:1 ratio to either of two interventions: 1. Placebo: daily consumption of the placebo tablet 2. Treatment: daily consumption of the supplement (treatment) tablet In addition, subjects will complete the WURSS-24 survey daily, and the APSQ survey weekly.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Provide informed consent by signing the electronic Information and Consent Form. - Male or females between the ages of 18 and 30 (inclusive) without regard to race or ethnic background - Are in generally good health and have no medical conditions that would prevent or interfere with their participation in the study - Are fully able and willing to comply with the requirements of the study - Are fully able and willing to keep scheduled appointments Exclusion Criteria: - Females that are pregnant, attempting to become pregnant or are currently lactating/nursing a child. - Individuals currently taking prescription medications that are known to be immunosuppressants (e.g. dexamethasone, tacrolimus, methotrexate) - Individuals with gastrointestinal conditions (e.g., inflammatory bowel disease, Crohn's disease, etc.) that may affect consumption of the treatment supplements. - Individuals with clinically important renal, hepatic, cardiac pulmonary, pancreatic, neurologic or biliary disorders; insulin-dependent and orally controlled diabetics will also be excluded from the study. - Individuals with a recent history of cancer other than non-melanoma skin cancer. - Individual's that have trouble swallowing pills. - Individuals that have participated as a subject in any other clinical study within 30 days of screening. - Individuals with a history of alcohol abuse or other substance abuse within the previous 2 years. - Individuals that currently use tobacco products including chewing tobacco and cigarettes.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Treatment
Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
Other:
Placebo
Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.

Locations

Country Name City State
United States US Ski and Snowboard Center of Excellence Park City Utah

Sponsors (1)

Lead Sponsor Collaborator
USANA Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Upper respiratory tract symptoms The frequency, duration and severity of upper respiratory tract symptoms among study participants will be monitored via a self reported questionnaire administered daily. 6 weeks
Secondary Athlete psychological stress The degree of athlete psychological stress symptoms among study participants will be monitored via a self reported questionnaire administered weekly. 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT01158560 - A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections Phase 3
Completed NCT00965822 - A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population Phase 2
Completed NCT01019889 - Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection Phase 3
Not yet recruiting NCT05484102 - Preventive Effect of Cow's Milk Fermented With Lactobacillus Paracasei CBA L74 on Common Infectious Diseases in Children N/A
Recruiting NCT05804123 - LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media N/A
Completed NCT01773824 - Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care N/A
Terminated NCT01964885 - Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections Phase 3
Completed NCT01883427 - Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children Phase 2
Completed NCT01215682 - Vitamin D Supplementation and Upper Respiratory Tract Infections in Adolescent Swimmers N/A
Completed NCT04019730 - The Effect of a Ketogenic Diet on the Exercise Induced Immune Response N/A
Completed NCT01604096 - Controlled Trial to Evaluate a Local Information Campaign on Antibiotic Prescribing in Italy Phase 2
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Completed NCT03463694 - Edinburgh and Lothian Virus Intervention Study in Kids N/A
Completed NCT06127186 - Phenotype of Headache and Facial Pain in Upper Respiratory Tract Infections
Completed NCT03198676 - A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production Phase 1
Withdrawn NCT05557214 - Reducing Unnecessary Antibiotic Prescriptions in Primary Healthcare in Saskatchewan by Identifying High Prescribers N/A
Completed NCT01893762 - Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes N/A
Completed NCT01396889 - Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years N/A
Completed NCT01129128 - Three Arm Trial of Immune Effects of Echinacea N/A
Completed NCT05252468 - COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19). N/A